Business Context and Reporting Period
Company: Albemarle Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1997
Business Overview: Following the March 1996 sale of its Olefins Business to Amoco, Albemarle operates in Bromine Chemicals, Specialty Chemicals, Surfactants, and Biocides. Effective July 24, 1997, the company realigned these into Polymer Chemicals, Fine Chemicals, and Potassium and Chlorine Chemicals.
Key Financial Metrics
| Metric (in thousands) | Q2 1997 | Q2 1996 | YTD 6mo 1997 | YTD 6mo 1996 |
|---|---|---|---|---|
| Net Sales | $207,675 | $196,039 | $406,069 | $466,210 |
| Gross Profit | $67,809 | $56,773 | $134,171 | $130,884 |
| Gross Margin | 32.7% | 29.0% | 33.0% | 28.1%* |
| Operating Profit | $32,312 | $20,383 | $64,678 | $53,823 |
| Net Income | $20,363 | $14,635 | $40,540 | $130,259 |
| Earnings Per Share | $0.37 | $0.26 | $0.73 | $2.10 |
| Cash & Equivalents | $3,858 | $14,242 | $3,858 | $44,292 |
| Long-Term Debt | $38,073 | $24,406 | $38,073 | $24,406 |
*YTD 1996 Gross Margin includes the Olefins Business; excluding it, the margin was 31.7%.
Material Changes vs. Prior Period
- Revenue: Q2 1997 sales increased 6% year-over-year due to higher shipments of flame retardants, zeolites, ibuprofen, and bromine fine chemicals. YTD sales decreased 13% primarily because the 1996 period included two months of sales from the Olefins Business prior to its March 1996 sale.
- Profitability: Operating profit rose 59% in Q2 and 20% YTD. Gross margins improved due to better plant utilization, cost reduction programs, and lower naproxen costs in 1997.
- Net Income Volatility: YTD 1996 Net Income ($130.3M) was significantly inflated by a $158.2M gain on the sale of the Olefins Business. Excluding this one-time gain, 1997 operating performance shows strong growth.
- Debt & Liquidity: Long-term debt increased to $38.1M from $24.4M. Cash and cash equivalents declined to $3.9M from $14.2M at year-end 1996, driven by capital expenditures ($52.3M YTD) and working capital increases.
Guidance, Outlook, and Risks
- Outlook: Management anticipates cash flow from operations will be sufficient to cover expenses, debt service, and dividends. Capital expenditures for the full year are forecasted to be slightly above 1996 levels.
- Product Developments:
- Naproxen: Start-up costs are decreasing, but FDA and European regulatory approvals are slower than anticipated.
- Urease Inhibitor: Sales of this new agricultural product are developing slower than expected.
- Flame Retardants: Two new chemicals are being introduced; customer acceptance remains a key variable.
- Potassium & Chlorine Chemicals: Cost reduction is necessary to break even; performance depends on demand for TV glass applications.
- Risks & Contingencies:
- Legal: Three OSHA citations regarding fires at a former plant were settled for less than $100,000. The EPA/DOJ has threatened suit regarding VOC emissions at the Orangeburg, SC plant, demanding a $530,000 penalty; settlement negotiations are ongoing.
- Regulatory: Compliance with environmental laws is expected to continue without material effect on earnings, though the company faces potential liability under Superfund laws.
- Accounting Changes: The company has not yet determined the impact of new FASB standards (SFAS 128, 130, 131) effective late 1997, though no material impact is expected.
Investor Verification Checklist
- Regulatory Approvals: Verify the status of FDA and European approvals for the naproxen product, as delays impact revenue projections.
- Legal Settlements: Monitor the outcome of the EPA/DOJ settlement negotiations regarding the Orangeburg plant emissions.
- Debt Levels: Confirm the trajectory of long-term debt, which rose significantly in the first half of 1997 to fund capital expenditures.
- Product Mix: Assess the success of new flame retardant introductions and the sales trajectory of the urease inhibitor.
- Foreign Currency: Note the 81% decrease in foreign currency translation adjustments due to the strengthening U.S. dollar, which impacts reported equity.